We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ILMN Stock Gains Following Expanded Collaboration With Labcorp
Read MoreHide Full Article
Key Takeaways
ILMN rises 1.8% after expanding collaboration with Labcorp to advance precision oncology solutions.
Illumina and Labcorp will co-commercialize liquid biopsy and tumor profiling tests to expand access.
ILMN collaboration aims to drive CGP adoption, with studies showing over 72% tumor variant detection.
Illumina, Inc. (ILMN - Free Report) and Labcorp (LH - Free Report) recently expanded their collaboration to advance precision oncology by leveraging innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem.
This collaboration is expected to strengthen Illumina’s position in the fast-growing oncology space.
ILMN Stock’s Likely Trend Following the News
Since the announcement, ILMN’s shares have gained 1.8%, closing at $122.95 yesterday.
An expanding NGS oncology portfolio is helping Illumina drive the revolution in cancer genomics. The company’s TruSight Oncology assay, TSO 500, continues to see increased utilization and broader adoption. Illumina is also partnering with several global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TSO Comprehensive genomic profiling test.
Illumina’s collaboration with Labcorp is expected to promote equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings. It will also generate evidence to facilitate payer coverage and develop new tests to address areas of unmet need. We expect the news to further boost market sentiment toward ILMN stock.
Illumina presently has a market capitalization of $18.48 billion. The company’s earnings yield of 4.25% sits comfortably against the industry’s -15.13%. It delivered a trailing four-quarter average earnings surprise of 10.1%.
Perks of Illumina’s Expanded Collaboration
As part of the collaboration, the companies will explore co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio plasma focus Dx, alongside Illumina's FDA-approved TruSight Oncology Comprehensive for solid tumor profiling. Together, these distributed in vitro diagnostic (IVD) test kits are intended to expand access to both tissue and liquid biopsy testing for hospitals and community health systems.
The collaboration will develop new tests, which is expected to span advanced oncology research and IVD tests for comprehensive genomic profiling (CGP) and whole-genome sequencing (WGS).
More on Illumina’s Collaboration With Labcorp
Illumina and Labcorp will continue joint efforts to demonstrate the clinical utility of CGP and promote its adoption. In a collaborative study published in Frontiers of Oncology, researchers evaluated more than 7,600 non-small cell lung cancer (NSCLC) tumor samples. The study applied Illumina CGP to demonstrate its coverage and utility in detecting known and novel genomic features of NSCLC.
Results showed that CGP identified variants associated with targeted therapies or clinical trials in more than 72% of tumor patients. This marks one of eight joint oncology publications between Illumina and Labcorp since 2022, along with 18 posters and presentations at industry conferences.
Industry Prospects Favor ILMN
Per a report by Global Market Insights, the global oncology market size is estimated to reach $866.1 billion in 2034, at a compound annual growth rate of 10.8% during 2024-2034. Key factors driving market growth include the rising global incidence of cancer, increasing disease awareness, and technological advancements.
Image Source: Zacks Investment Research
Another Recent Collaboration by ILMN
Last Tuesday, Illumina announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium. The partnership is aimed at bringing preventive genomics into everyday healthcare through health insurance plans in the United States and other global markets.
ILMN Stock Price Performance
Over the past year, ILMN’s shares have risen 44.4% compared with the industry’s 12.7% growth.
Illumina’s Zacks Rank and Key Picks
Illumina currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.5% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.1%.
Intuitive Surgical, sporting a Zacks Rank #1 at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, which outpaced the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.2%.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
ILMN Stock Gains Following Expanded Collaboration With Labcorp
Key Takeaways
Illumina, Inc. (ILMN - Free Report) and Labcorp (LH - Free Report) recently expanded their collaboration to advance precision oncology by leveraging innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem.
This collaboration is expected to strengthen Illumina’s position in the fast-growing oncology space.
ILMN Stock’s Likely Trend Following the News
Since the announcement, ILMN’s shares have gained 1.8%, closing at $122.95 yesterday.
An expanding NGS oncology portfolio is helping Illumina drive the revolution in cancer genomics. The company’s TruSight Oncology assay, TSO 500, continues to see increased utilization and broader adoption. Illumina is also partnering with several global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TSO Comprehensive genomic profiling test.
Illumina’s collaboration with Labcorp is expected to promote equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings. It will also generate evidence to facilitate payer coverage and develop new tests to address areas of unmet need. We expect the news to further boost market sentiment toward ILMN stock.
Illumina presently has a market capitalization of $18.48 billion. The company’s earnings yield of 4.25% sits comfortably against the industry’s -15.13%. It delivered a trailing four-quarter average earnings surprise of 10.1%.
Perks of Illumina’s Expanded Collaboration
As part of the collaboration, the companies will explore co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio plasma focus Dx, alongside Illumina's FDA-approved TruSight Oncology Comprehensive for solid tumor profiling. Together, these distributed in vitro diagnostic (IVD) test kits are intended to expand access to both tissue and liquid biopsy testing for hospitals and community health systems.
The collaboration will develop new tests, which is expected to span advanced oncology research and IVD tests for comprehensive genomic profiling (CGP) and whole-genome sequencing (WGS).
More on Illumina’s Collaboration With Labcorp
Illumina and Labcorp will continue joint efforts to demonstrate the clinical utility of CGP and promote its adoption. In a collaborative study published in Frontiers of Oncology, researchers evaluated more than 7,600 non-small cell lung cancer (NSCLC) tumor samples. The study applied Illumina CGP to demonstrate its coverage and utility in detecting known and novel genomic features of NSCLC.
Results showed that CGP identified variants associated with targeted therapies or clinical trials in more than 72% of tumor patients. This marks one of eight joint oncology publications between Illumina and Labcorp since 2022, along with 18 posters and presentations at industry conferences.
Industry Prospects Favor ILMN
Per a report by Global Market Insights, the global oncology market size is estimated to reach $866.1 billion in 2034, at a compound annual growth rate of 10.8% during 2024-2034. Key factors driving market growth include the rising global incidence of cancer, increasing disease awareness, and technological advancements.
Image Source: Zacks Investment Research
Another Recent Collaboration by ILMN
Last Tuesday, Illumina announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium. The partnership is aimed at bringing preventive genomics into everyday healthcare through health insurance plans in the United States and other global markets.
ILMN Stock Price Performance
Over the past year, ILMN’s shares have risen 44.4% compared with the industry’s 12.7% growth.
Illumina’s Zacks Rank and Key Picks
Illumina currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.5% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.1%.
Intuitive Surgical, sporting a Zacks Rank #1 at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, which outpaced the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.2%.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 9.3%.